Relentless is this market in it’s downward swoon. NASDAQ is back to where it was in December 2005! We joined the market last week again, despite booking a 40% gain on the OPTIO buy-out. We got nailed with a 30%+ loss on PDLI as well as others to post a 5.4% loss last week. We have not seen some of these type of valuations since 2002 and they just keep getting cheaper every week. The sky was falling then too. But it didn’t fall. Stock prices rose. We took the plunge last week and added to PARL, PDLI and BDAY.

All of the major averages have lost all their 2007 gains and then some from 12/31/2006. And we have too.

We were down 5.4% last week, bringing our YTD 2008 loss to 33.3%. NASDAQ was down 2.6%, the DOW was down 3.1% and the S+P 500 was down 2.8%. There are lots of cheap stocks around now, but we keep coming back to the ones we already own as being the best values.

Last week we went 4 stocks up and 11 down.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -5.4%,-33.1 and +.6% respectively. Since inception we are now 19 stocks up and 12 down.

So far in 2008 the DOW is down 10.3%, NASDAQ is down 16.6% and the S+P 500 is down 11.9%. The NASDAQ is now down a whopping 22.6% since October 31, 2007.

The Russell 3000 and the Wilshire 5000 are both down just about 12% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%
2008-OPTO.ob +40% (Buy-out offer)

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 18 stocks that we closed out in 2006, 2007 and 2008 the average gain was 23%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $9.40 (was $10.65 before double up), Valuation $20-$22
Down $.59 to $8.41.
SPNC gave back the prior weeks gains.
The company has $54.4 million in cash ($1.73 per share–21% of the current share price), and is trading at about 2 times 2008 revenues (net of cash). Stupid.
Now down 11%. BUY.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $3.40, down $.05.
DWCH is now trading at 38% of our valuation.
We bought more last week around $3.30.
No news.
Now up 8%. BUY

Parlux Fragrances (PARL-Recommended 11/30/2006)
New Buy price $4.14 (was $4.78 before $10,000 adder, $6.12 before another $10,000 added, $6.65 before double up), Valuation $11.24 (Was $10.80 $9.20, $8.63, $13.77)
PARL closed at $2.87, down $.51.
Latest earnings were very good. Stock is down. The market in general is anticipating that the bottom will fall out of everything.
Now trading at 26% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
We bought more last week under $3.00.
Down 31%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $10.60 up $.76.
The over $1 price rise in this crappy market over the last 2 weeks, may signal a buy-out is near–lets hope so. Seems that this is the only way for any stock to go up this year.
Our valuation moved back up to over $24 per share.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 12%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
NEW Buy Price $6.15 (was $8.38 before $10,000 adder and $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.74 to $4.39.
There will be no more birthdays or halloween. BDAY is not burning it up, but this is stupid.
Trading at 28% of our valuation.
The “turnaround” is not yet done.
Down 29%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) Valuation $10.28 (was $13.32, $12.89, $13.40)
Down $.12 to $6.00.
Cannell Capital filed a 13D on February 19th, disclosing a 12.9% ownership stake. Most of this was purchased from Penninsula at $7.03 a share. Cannell is pushing MEDW management to sell the company. It seems the only was any stock can go up these days is on a buy-out.
Down 8%. HOLD

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $8.69 (was $11.51)
Down $.61 to $3.91
No news.
Down 46%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Down $.30 to $1.80.
Trading at 24% of our valuation
Down 25%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
New Buy Price $14.15 (was $16.53 before $10,000 adder, and $20.04 before double-up), Valuation $18.00 to $20.00
Down $4.85 to $11.13.
PDLI announced that they decided to dissappoint everyone last week and not sell the company. So it got the customary 30%+ market haircut.
Instead of doing what they said they were going to do, they took the company off the block and announced that they will pay out over $500 million of the asset sale proceeds, when they get them, and then sometime after that. Oh yeah, they will do other things to get the shareholders some value too. These guys have been entirely inept so far.
But, we still think the company is worth way more than $11. So we added some more last week.
Down 21%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $10.66 (Was, $9.39)
Down $.02 to $4.04.
No news.
Trading at only 38% of our valuation.
Down 6%. BUY

OB-abies (Bulletin Board Listed Stocks)

Interestingly, our OB-abies have held up better than the “higher-quality” stocks so far this year. They are down about 3% on average, compared to almost 23% for the stocks above. At least so far.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.85, up $.07.
Earnings announced in January were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Earnings due out Monday, March 17th, before the open.
Now up 15%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
SOLD last week at $1.75 for a 40% gain. Took a while, but it did happen.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.41 (was $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.85, down $.03.
Earnings out in early February. Sales up only 4%, but earnings up 69%!. EPS was $.04 compared to $.02 last year. Pre-tax earnings were up over 100%. Our valuation rose to $3.41. Stock goes down. Who can figure.
Now down 9%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price down $.04 at $.29. Closed at $.24.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 25% of our latest valuation.
Up 7% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $.95 (Was $1.08 before double-up) Valuation $2.08
Closed at $.84, up $.03.
LTUS announced a $5 million private placement of stock in late February. 5,547,000 shares and warrants to purchase another 2.9 million shares at $1.20. Also in the agreement, the current big holders have to put up a chunk of their personal stock in escrow, which will be released on hitting certain earnings target. The target for 2007 is $8.5 million. For the 9 months ended September 30, they made $6.1 million. So this should make $2.4 million Q4 earnings a slam dunk–$.05 per share. Target for 2008 is $13.8 million (about $.28 a share) and 2009–$17.5 million or about $.35 per share. This is still a BUY.
Down 11%.

This market has been relentlessly depressing. NASDAQ is down over 22% since October 31, 2007. But we can not stand it anymore. We are taking the 40% profit from the Optio takeover announced this week and putting an additional $10,000 into each of PDLI, BDAY and PARL. The adjusted average buy prices for these will be:

BDAY–$6.15
PDLI–$14.15
PARL–$4.14

The reaction to the PDLI news this week that they are not selling the company was crazy in our opinion, but anything less that great news seems to warrant a 30% haircut in this market.

Bottomline Technologies offered to buy Optio this morning. Obviously this is why the company has been so quiet lately. Buy-out price is $1.85 a share. Less than we think OPTIO is worth–but in this market, we will take it.

Bottomline has the cash to do this deal, so the risk here is minimal for the deal not to go through. Nevertheless, we will not wait. Sell at $1.75 a share or better for a 40% gain on this one.

Back to the dismal 2008 markets again last week. We managed to finally avoid the plunge and post a 3.9% gain last week on the strenght of CLZR (+30%) and MIVA (+19%). We have not seen some of these type of valuations since 2002. The sky was falling then too. But it didn’t fall. Stock prices rose. If we were not so heavily weighted in DWCH, PARL, ILOG, BDAY and MIVA, we would add more in these also.

All of the major averages have lost all their 2007 gains and then some from 12/31/2006. And we have too.

We were up 3.9% last week, bringing our YTD 2008 loss to 27.9%. NASDAQ was down 1.4%, the DOW was down .9% and the S+P 500 was down 1.7%. There are lots of cheap stocks around now, but we keep coming back to the ones we already own as being the best values.

Last week we went 8 stocks up, 6 down and 1 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is +3.9%,-27.9 and +6.2% respectively. Since inception we are now 18 stocks up, 13 down and 1 even.

So far in 2008 the DOW is down 7.5%, NASDAQ is down 14.4% and the S+P 500 is down 9.4%. The NASDAQ is now down a whopping 21% since October 31, 2007.

The Russell 3000 and the Wilshire 5000 are both down just about 9.2% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 17 stocks that we closed out in 2006, 2007 and 2008 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Up $.58 to $9.00.
SPNC seems to have stabilized after last weeks disaster. Some insider buying has helped it appears. A stock but-back would solidify this, we think.
The company has $54.4 million in cash ($1.73 per share–21% of the current share price), and is trading at about 2 times 2008 revenues (net of cash).
Now down 4%. BUY.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $3.45, down $.16.
DWCH is now trading at 38% of our valuation.
No news.
Now up 10%. BUY

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $11.24 (Was $10.80 $9.20, $8.63, $13.77)
PARL closed at $3.38, down $.19.
Latest earnings were very good. Stock is down. The market in general is anticipating that the bottom will fall out of everything.
Now trading at 30% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 29%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $9.84 up $.50.
Our valuation moved back up to over $24 per share.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 19%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.10 to $5.13.
There will be no more birthdays or halloween. BDAY is not burning it up, but this is stupid.
Trading at 33% of our valuation.
The “turnaround” is not yet done.
Down 39%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) Valuation $10.28 (was $13.32, $12.89, $13.40)
Down $.30 to $6.12.
Cannell Capital filed a 13D on February 19th, disclosing a 12.9% ownership stake. Most of this was purchased from Penninsula at $7.03 a share. Cannell is pushing MEDW management to sell the company. It seems the only was any stock can go up these days is on a buy-out.
About 45,000 shares purchased by insiders last week at $6.15. Always a good sign.
Down 6%. HOLD

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $8.69 (was $11.51)
Up $1.05 to $4.52
No news, but apparently there are “industry consolidation” rumors.
Down 38%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Up $.34 to $2.10 in late Friday feeding frenzy.
Trading at 23% of our valuation
Down 12%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $16.53 (was $20.04 before double-up), Valuation $24.00 to $30.00
Up $.23 to $15.98.
PDLI announced the sale of their manufacturing assets in February for $240 million.
So total cash deals are $525 million (about $5.25 per share). They are still trying to sell their royalty stream.
We guess their royalty stream just based on the current marketed products is worth at least $1.5 billion, so this, plus the sales above, are more that the current market cap. Their pipeline, know-how, and remaining assets just add to this.
No matter, they are still trying to sell the company.
Down 3%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $10.66 (Was, $9.39)
Up $.08 to $4.06.
No news.
Trading at only 38% of our valuation.
Down 5%. BUY

OB-abies (Bulletin Board Listed Stocks)

Interestingly, our OB-abies have held up better than the “higher-quality” stocks so far this year. They are down about 8.6% on average, compared to almost 14% for the stocks above. At least so far.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.78, down $.07.
Earnings announced in January were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 10%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.25, up $.07.
OPTIO has cash of $.41 per share–33% of the market cap.
In June 2007, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division.
It has been over 8 months now since their announcement–with no announcement. We have to assume there will be no deal here. Management is derelict in making no announcement.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers.
EVEN. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.41 (was $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.88, up $.05.
Earnings out in early February. Sales up only 4%, but earnings up 69%!. EPS was $.04 compared to $.02 last year. Pre-tax earnings were up over 100%. Our valuation rose to $3.41. Stock goes down. Who can figure.
Now down 6%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price down $.01 at $.33. Closed at $.28.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 28% of our latest valuation.
Up 22% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $.95 (Was $1.08 before double-up) Valuation $2.08
Closed at $.81, unchanged.
LTUS announced a $5 million private placement of stock last week. 5,547,000 shares and warrants to purchase another 2.9 million shares at $1.20. Also in the agreement, the current big holders have to put up a chunk of their personal stock in escrow, which will be released on hitting certain earnings target. The target for 2007 is $8.5 million. For the 9 months ended September 30, they made $6.1 million. So this should make $2.4 million Q4 earnings a slam dunk–$.05 per share. Target for 2008 is $13.8 million (about $.28 a share) and 2009–$17.5 million or about $.35 per share. This is still a BUY.
Down 14%.

Small rebound in the markets last week (except for NASDAQ). Still, the overall direction is down and good news continues to get no respect (See SPNC update). We are doubling up on SPNC. We have not seen some of these type of valuations since 2002. The sky was falling then to. But it didn’t fall. The stock prices rose. If we were not so heavily weighted in DWCH, PARL, ILOG, BDAY and MIVA, we would add more in these also.

All of the major averages have lost all their 2007 gains and then some from 12/31/2006. And we have too.

We were down 4.1% last week on the amazing 34% plunge in SPNC–on a good earnings report, bringing our YTD 2008 loss to 31.8%. NASDAQ was down .8%, the DOW was up .3% and the S+P 500 was up .2%. There are lots of cheap stocks around now, but we keep coming back to the ones we already own as being the best values.

Last week we went 9 stocks up, 5 down and 1 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -4.1%,-31.8 and +2.0% respectively. Since inception we are now 18 stocks up and 14 down.

So far in 2008 the DOW is down 6.7%, NASDAQ is down 13.2% and the S+P 500 is down 7.8%

The Russell 3000 and the Wilshire 5000 are both down just under 8% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006, 2007 and 2008 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Down $4.28 to $8.42.
What a disaster. SPNC reports a sales increase of 35% and the stock plummets. They lost $89,000 for the quarter–after a 114% non-cash tax provision, non-cash stock compensation expense (not disclosed) and duplicate facility costs for their new manufacturing plant (not disclosed). “Talk” is the stock plunged because they missed analysts $.02 earnings guess ($600,000), or that their guidance for 2008 (25%–33% revenue growth was disappointing. No one really knows, but the panic hit SPNC hard–$134 million of market value lost last week alone.
The company has $54.4 million in cash ($1.73 per share–21% of the current share price), and is trading at about 2 times 2008 revenues (net of cash). This is stupid. We are doubling up here (another $10,000 investment).
Obviously SPNC management did not manage street expectations AT ALL. Otherwise this would not have happened.
New avg. Buy price will be $9.40.
Now down 21%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $3.61, up $.03.
DWCH is now trading at 39% of our valuation.
No news.
Now up 15%. BUY

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $11.24 (Was $10.80 $9.20, $8.63, $13.77)
PARL closed at $3.57, up $.12.
Latest earnings were very good. Stock is down. The market in general is anticipating that the bottom will fall out of everything.
Now trading at 31% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 25%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $9.34 up $.30.
Our valuation moved back up to over $24 per share.
No one cares in this market. ANY negative comment, or lack of positive comment weighs on share pricing these days.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 23%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Up $.10 to $5.23.
There will be no more birthdays or halloween. BDAY is not burning it up, but this is stupid.
Trading at 33% of our valuation.
The “turnaround” is not yet done.
Down 38%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) Valuation $10.28 (was $13.32, $12.89, $13.40)
Up $.26 to $6.42.
Cannell Capital filed a 13D on February 19th, disclosing a 12.9% ownership stake. Most of this was purchased from Penninsula at $7.03 a share. Cannell is pushing MEDW management to sell the company. It seems the only was any stock can go up these days is on a buy-out.
Down 2%. HOLD

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $8.69 (was $11.51)
Down $.24 to $3.47
No much going on here.
Down 52%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Up $.09 to $1.76.
Trading at 23% of our valuation
Down 26%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $16.53 (was $20.04 before double-up), Valuation $24.00 to $30.00
Up $.12 to $15.75.
PDLI announced the sale of of their manufacturing assets last week for $240 million.
So total cash deals are $525 million (about $5.25 per share). They are still trying to sell their royalty stream.
After the market close on Friday DNA announced the FDA appoved Avastin for treatment of breast cancer. This just increased the value of the royalty stream.
We guess their royalty stream just based on the current marketed products is worth at least $1.5 billion, so this, plus the sales above, are more that the current market cap. Their pipeline, know-how, and remaining assets just add to this.
No matter, they are still trying to sell the company.
Down 5%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $10.66 (Was, $9.39)
Up $.02 to $3.98.
No news.
Trading at only 37% of our valuation.
Down 7%. BUY

OB-abies (Bulletin Board Listed Stocks)

Interestingly, our OB-abies have held up better than the “higher-quality” stocks so far this year. They are down about 9% on average, compared to almost 18% for the stocks above. At least so far.

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.85, up $.05.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 15%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.18, down $.02.
OPTIO has cash of $.41 per share–35% of the market cap.
In June 2007, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division.
It has been over 8 months now since their announcement–with no announcement. We have to assume there will be no deal here. Management is derelict in making no announcement.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers.
Down 6%. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.41 (was $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.83, down $.01.
Earnings out in early February. Sales up only 4%, but earnings up 69%!. EPS was $.04 compared to $.02 last year. Pre-tax earnings were up over 100%. Our valuation rose to $3.41. Stock goes down. Who can figure.
Now down 11%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.24.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $.95 (Was $1.08 before double-up) Valuation $2.08
Closed at $.81, down $.03.
LTUS announced an earnings restatement 2 weeks ago–OH NO!–but wait–they are restating their earnings UP–so the stock falls. This is all part of the market irrationallity right now.
Looks like they are catching up on their restatements per their SEC filings last week.
Down 14%. BUY

Small rebound in the markets for a while last week. Still, the overall direction is down and good news continues to get no respect (See AVSO.ob update). We are doubling up on LTUS.ob. We have not seen some of these type of valuations since 2002. The sky was falling then to. But it didn’t fall. The stock prices rose. If we were not so heavily weighted in DWCH, PARL, ILOG, BDAY and MIVA, we would add more in these also.

All of the major averages have lost all their 2007 gains and then some from 12/31/2006. And we have too.

We were down 2.3% last week, bringing our YTD 2008 loss to 27.7%. NASDAQ was up .7%, the DOW was up 1.4% and the S+P 500 was up 1.4%.

Last week we went 9 stocks up, 5 down and 1 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -2.3%,-27.7 and +6.5% respectively. Since inception we are now 19 stocks up and 13 down.

So far in 2008 the DOW is down 6.9%, NASDAQ is down 12.5% and the S+P 500 is down 8.1%

The Russell 3000 and the Wilshire 5000 are both down just under 8% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006, 2007 and 2008 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Up $.40 to $12.70.
Earnings due on 2/20 beofre the open. Keep your fingers crossed.
Now up 19%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $3.58, up $.o4.
DWCH is now trading at 39% of our valuation.
No news.
Now up 14%. BUY

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $11.24 (Was $10.80 $9.20, $8.63, $13.77)
PARL closed at $3.45, down $.13.
Latest earnings were very good. Stock is down. The market in general is anticipating that the bottom will fall out of everything.
Now trading at 31% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 28%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $9.04 up $.26.
Our valuation moved back up to over $24 per share.
No one cares in this market. ANY negative comment, or lack of positive comment weighs on share pricing these days.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 24%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.28 to $5.13.
There will be no more birthdays or halloween. BDAY is not burning it up, but this is stupid.
Trading at 33% of our valuation.
The “turnaround” is not yet done.
Down 39%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) Valuation $10.28 (was $13.32, $12.89, $13.40)
Up $.49 to $6.16.
Earnings out last week.
The stock buy-back seems to have stopped the hemmoraging for now.
No news.
Down 6%. HOLD

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $8.69 (was $11.51)
Up $.20 to $3.71
No much going on here.
Down 49%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Down $.31 to $1.67.
Euphoria from Yahoo deal seems to have worn off.
Trading at 22% of our valuation
Down 30%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $16.53 (was $20.04 before double-up), Valuation $24.00 to $30.00
Up $1.14 to $15.63.
PDLI announced the sale of of their remaining cardiovascular products–back to the guys they bought them from for a less than robust $85 million, future royalties on yet to be developed products and some possible future milestone payments.
So total cash deals are $285 million (about $2.40 per share). They are still trying to sell their royalty stream and R+D and manufacturing assets.
We guess their royalty stream just based on the current marketed products is worth $1.5 billion, so this, plus the sales above, are more that the current market cap. Their pipeline, know-how, and remaining commercial assets just add to this.
No matter, they are still trying to sell the company.
Down 6%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $10.66 (Was, $9.39)
Up $.05 to $3.96.
No news.
Trading at only 37% of our valuation.
Down 8%. BUY

OB-abies (Bulletin Board Listed Stocks)

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.80, up $.06.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 12%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.20, down $.05.
OPTIO has cash of $.41 per share–34% of the market cap.
In June 2007, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division.
It has been over 8 months now since their announcement–with no announcement. We have to assume there will be no deal here. Management is derelict in making no announcement.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers.
Down 4%. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.05 (was $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.84, up $.02.
Earnings out last week. Sales up only 4%, but earnings up 69%!. EPS was $.04 compared to $.02 last year. Pre-tax earnings were up over 100%. Our valuation rose to $3.41. Stock went down. Who can figure.
Now down 10%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.24.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.08 Valuation $2.08
Closed at $.84, down $.06.
LTUS announced an earnings restatement last week–OH NO!–but wait–they are restating their earnings UP–so the stock falls. This is all part of the market irrationallity right now. We may continue to buy more if the price stays in this range. Double up here. New avg Buy Price will be $.95 next week.
Down 22%. BUY

Sorry everyone. Hard to stand up to a tsunami. The third (or was it the fourth) wave hit last week. Even good earnings reports are being throw overboard (see DTLK and PARL updates) and less than good ones are being trashed (see MEDW update).

All of the major averages have lost all their 2007 gains and then some from 12/31/2006. This third wave caught up with us also.

We were down 11% last week, bringing our YTD 2008 loss to 25.4%. NASDAQ was down 4.5%, the DOW was down 4.4% and the S+P 500 was down 4.6%.

Last week we went 3 stocks up, 11 down and 1 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -11%,-25.4 and +9.1% respectively. Since inception we are now 19 stocks up and 12 down and 1 even.

So far in 2008 the DOW is down 8.2%, NASDAQ is down 13.1% and the S+P 500 is down 9.3%

The Russell 3000 and the Wilshire 5000 are both down just under 9% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006, 2007 and 2008 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Down $.90 to $12.30.
No news. Just waiting for earnings and 2008 guidance.
Things continue to look just fine here.
Now up 16%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $3.54, down $.47.
The swoon continued. Probably fueled by some margin selling and the market in general.
DWCH is now trading at 39% of our valuation.
Now up 13%. BUY

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), NEW Valuation $11.24 (Was $10.80 $9.20, $8.63, $13.77)
PARL closed at $3.58, down $.23.
Earnings last week were very good. So the stock only went down a little!
Sales were up about 3% to $44.5 million, they made $.01 per share and ended the quarter with net cash off about $10 million.
Operating earnings were $494,000 compared to a loss of $8,218,000 last year.
Our valuation rose to $11.24.
Now trading at 32% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 25%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $9.04 down $1.16.
Our valuation moved back up to over $24 per share.
No one cares in this market. ANY negative comment, or lack of positive comment weighs on share pricing these days.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 25%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.55 to $5.41.
BDAY announced earnings in early January. We thought they were pretty good. Apparently the market did not agree. Sales were up 10%, gross margin was up to 53%, but operating income was down from $568,000 to $430,000. So we have lost $25 million of market cap for a $138,000 decline in operating income. Cash was $18.7 million or $2.34 per share–43% of the market cap.
From their conference call, it sounds like 2008 will be a year of continued investment in systems and the business. So maybe no great earnings to propel the stock for a while.
The “turnaround” is not yet done.
Down 35%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) NEW Valuation $10.28 (was $13.32, $12.89, $13.40)
Down $1.37 to $5.67.
Earnings out last week.
Another dissappointment.
Sales down 23%, and they lost $.04 a share.
Cash was $21 million or $2.48 a share. 44% of market cap.
A $4 million share buyback was announced by the Company last week which seemed to stop the bleeding a bit.
Our valuation fell to $10.28.
Down 13%. HOLD

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $8.69 (was $11.51)
Down $.06 to $3.51
No much going on here.
Down 51%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Down $.40 to $1.98.
Euphoria from Yahoo deal (which looks like it will be rejected by Yahoo) seems to have worn off.
Down 17%. Hold

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $16.53 (was $20.04 before double-up), Valuation $24.00 to $30.00
Down $.71 to $14.49.
PDLI announced the sale of of their remaining cardiovascular products–back to the guys they bought them from for a less than robust $85 million, future royalties on yet to be developed products and some possible future milestone payments.
So total cash deals are $285 million (about $2.40 per share). They are still trying to sell their royalty stream and R+D and manufacturing assets.
We guess their royalty stream just based on the current marketed products is worth $1.5 billion, so this, plus the sales above, are more that the current market cap. Their pipeline, know-how, and remaining commercial assets just add to this.
No matter, they are still trying to sell the company.
Down 12%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, NEW Valuation $10.66 (Was, $9.39)
Down $.26 to $3.91.
Earnings last week were terrific. So fortunately we only FELL $.26.
Sales were up 31% to $50.7 million. EPS was $.11 (GAAP and fully taxed).
Cash (no debt)was $25 million or $2.03 per share (more than 50% of market cap.)
Margins stayed steady at 26%.
Our valuation moved up to $10.66 per share.
Apparently the excuse for the stock not soaring was weak guidance-they only expect sales to be up 10-20% over last year and only inpoved EPS by $.06 to $.10 per share.
There really is nothing to do in this market but to close your eyes, hold on and wait for the irrational selling to stop.
Trading at only 37% of our valuation.
Down 9%. BUY

OB-abies (Bulletin Board Listed Stocks)

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.74, up $.01.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 8%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.25, up $.05.
OPTIO has cash of $.41 per share–33% of the market cap.
In June 2007, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division.
It has been over 8 months now since their announcement–with no announcement. We have to assume there will be no deal here. Management is derelict in making no announcement.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers.
EVEN. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.05 (was $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.82, down $.08.
Nice presentation filed in their 8K in December. Couple of nice mentions–including in Smart Money of the CEO interview with the Wall Street Reporter. Sigma Opportunity Fund has been buying more shares.
We are guessing $55 million of revenue this year and being profitable–which should yield a valuation of over $3.50 a share, and hopefully a share price of at least $2.00–up 100% from here.
Earnings due out Thursday, Feb. 14th before the market opens.
Now down 12%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.24.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.08 Valuation $2.08
Closed at $.90, up $.04.
LTUS announced the hiring of a PR firm in January.
LTUS, filed an impressive investor presentation on Form 8K in early December.
As noted, China stocks are risky, but based on their published information we just cannot figure out why this stock is trading so low.
LTUS is on track to make $.18 a share this year. Even if these earnings were taxed at U.S. tax rates, that would be about $.12 a share. That is a PE of less than 10, for a company growing revenues at 50% year-over-year. We may continue to buy more if the price stays in this range.
Down 17%. BUY

Well the markets had a good week last week. “Pigs get slaughtered”. I guess we were piggy on DWCH. It got slaughtered last week and slaughtered us. Down 37% last week.

All of the major averages have lost all their 2007 gains and then some except for the Dow which is now up 2.2% from 12/31/2006. While our year has stunk up the place–we are still holding on to about 5% of our 2007 gain. Really doesn’t make us feel too much better.

We were down 2.7% last week, (we would have been up 8% without DWCH) bringing our YTD 2008 loss to 14.5%. NASDAQ was up 3.75%, the DOW was up 4.4% and the S+P 500 was up 4.9%.

Selling ANGN at $9.51 turned out to be good move as it closed at $7.91 and our “double-up” on PDLI worked also as it rose from $14.07 to $15.20

Last week we went 8 stocks up, 5 down and 2 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -2.7%,-14.5% and +21.7% respectively. Since inception we are now 20 stocks up and 11( 5 of which are down less than 10%)and 1 even.

So far in 2008 the DOW is down 3.9%, NASDAQ is down 9.0% and the S+P 500 is down 5.0%

The Russell 3000 and the Wilshire 5000 are both down just under 5% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-ANGN +26%

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006, 2007 and 2008 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Up $.30 to $13.20.
Short interest rose again as the hackers are hard at work.
Things continue to look just fine here.
Now up 24%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), NEW Valuation $9.03 (was $10.30, $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $4.01, down $2.32.
Earnings last week. Sales rose only 5% and earnings came in at $.04. The 1 analyst that puts out estimates had expected $.10. We were happy sales rose, they made money and have $.65 a share in cash! Obviously other shareholders were not happy and dumped DWCH. There may have been some margin call selling too. Our valuation dropped–but to $9.03, about where it was before the previous quarterly report.
We bought a bit more on Friday at $3.97 for a small trade. But since we rarely average up, we are not recommending adding to this position officially.
DWCH is now trading at 44% of our valuation.
Now up 27%. HOLD

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $10.80 (Was $9.20, $8.63, $13.77)
PARL closed at $3.81, down $.13.
Lets see, last quarter sales were up 38%, made $.10 a share fully taxed and paid down $8 million of debt over the past 6 months.
ECOM Ventures announced that it will merge with Model Reorg. Inc. ECOM will pay for it with shares, so that Nussdorf and family will end up owning 70% of ECOM. So maybe this was why he has been selling some PARL shares–lots of expenses and maybe some taxes to pay?
If they can get this deal done, can one with PARL be far behind?
Now trading at 35% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Earnings out Monday–early.
Down 20%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), NEW Valuation $24.67 (was $20.51, $23.22, $20.99, $20.52)
Closed at $10.20 up $.21.
Earnings last week. Sales up 22%, EPS up 200%.
Our valuation moved back up to over $24 per share.
No one cares in this market. ANY negative comment, or lack of positive comment weighs on share pricing these days.
For FY2008 (this year) they are STILL projecting another 20% increase in sales but revised their earnings projections down. They still have $3.39 a share in cash.
A buy-out is a decent possibility here.
Down 16%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.13 to $5.96.
BDAY announced earnings in early January. We thought they were pretty good. Apparently the market did not agree. Sales were up 10%, gross margin was up to 53%, but operating income was down from $568,000 to $430,000. So we have lost $20 million of market cap for a $138,000 decline in operating income. Cash was $18.7 million or $2.34 per share.
From their conference call, it sounds like 2008 will be a year of continued investment in systems and the business. So maybe no great earnings to propel the stock for a while.
The “turnaround” is not yet done.
Down 29%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) NEW Valuation $13.32 (was $12.89, $13.40)
Up $.16 to $7.04.
Earnings out Tuesday, before the open.
UP 8%. BUY

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, New Valuation $8.69 (was $11.51)
Down $.72 to $3.57.
Hmm–earnings were out last week, not next week.
Not good for sure.
Sales down 3.5%, and they lost $4.5 million or $.20 per share.
Our valuation fell to $8.69. Still at 41% of our valuation, we are going to hold on for a while. This would probably be a “double-up” if it were not for the uncertainty of the Palomar patent litigation, ($3.9 million of legal expenses in this last quarter).
Down 51%. HOLD

Angeion Corp. (ANGN-Recommended 10/14/2007)
Buy Price $7.55, Valuation $13.67
SOLD at $9.51 for a 26% gain.

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Up $.60 to $2.38.
Yahoo takeover offer by Microsoft helped a bit.
EVEN. Hold

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $16.53 (was $20.04 before double-up), Valuation $24.00 to $30.00
Up $1.13 to $15.20.
PDLI announced the sale of a $30 million a year in sales drug–for $200 million.
At 7X the royalty revenue and 3X the product sales, you get $2.1 billion in value comapared to the current market cap of $2.1 billion. Their pipeline, and know-how has to be worth something.
No matter, they are still trying to sell the company.
So we are just waiting for them to announce the sale of the company and for how much.
Down 8%. HOLD

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $9.39
Up $.24 to $4.17.
There is value here.
Trading at only 44% of our valuation.
Earnings out Wednesday, February 6th after the close.
Down 3%. BUY

OB-abies (Bulletin Board Listed Stocks)

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.73, up $.11.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 7%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.20, up $.05.
OPTIO has cash of $.41 per share–34% of the market cap.
In late June, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division. In other words, a “for sale” sign has gone up. Having been through their SEC filings, there appears to be no disclosure on the sales or operating results for this “division”, so there is no way for us to determine what this could mean from a valuation standpoint.
It has been over 6 months now since their announcement–We would expect to hear an update SOON. They said in their latest earnings release that their healthcare business exceeded their goals. They better get a good price for this.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers, or they get a good deal on the Healthcare “division”.
Down 4%. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.05 (was $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.90, unchanged.
Nice presentation filed in their 8K in December. Couple of nice mentions–including in Smart Money of the CEO interview with the Wall Street Reporter. Sigma Opportunity Fund has been buying more shares.
We are guessing $55 million of revenue this year and being profitable–which should yield a valuation of over $3.50 a share, and hopefully a share price of at least $2.00–up 100% from here.
No news.
Now down 3%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.28.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.08 Valuation $2.08
Closed at $.86, down $.04.
LTUS announced the hiring of a PR firm in January. They need to get to work!
LTUS, filed an impressive investor presentation on Form 8K in early December.
As noted, China stocks are risky, but based on their published information we just cannot figure out why this stock is trading so low.
LTUS is on track to make $.18 a share this year. Even if these earnings were taxed at U.S. tax rates, that would be about $.12 a share. That is a PE of less than 10, for a company growing revenues at 50% year-over-year. We may continue to buy more if the price stays in this range.
Down 20%. BUY

Well at least the markets seem a little more stable last week than the rest of 2008. MIVA was our star last week–up 27%, followed by PARL up 19%. They had been beaten down so much that they had nowhere to go but up.

All of the major averages have lost all their 2007 gains and then some. While our year has stunk up the place–we are still holding onto about 8% of our 2007 gain. Really doesn’t make us feel too much better.

We were up 5.4% last week, cutting our YTD 2008 loss to 11.7%. NASDAQ was down .6%, the DOW was up .9% and the S+P 500 was up .4%.

This weeks advice–SELL ANGN at $9.51 for a 26% gain and double up on PDL.

Last week we went 7 stocks up, 8 down and 1 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is +5.4%,-11.7% and +24.9% respectively. Since inception we are now 20 stocks up and 12 down( 3 of which are down less than 10%).

So far in 2008 the DOW is down 8.0%, NASDAQ is down 12.3% and the S+P 500 is down 9.4%.

The Russell 3000 and the Wilshire 5000 are both down about 9.5% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006 and 2007 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Down $.40 to $12.90.
The market just stinks, hackers are at work (even though short interest dropped a bit)
Things continue to look just fine here.
Now up 21%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $10.30 (was $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $6.33, down $.24.
The ex-CEO keeps cashing in options and selling–another 20,000 shares sold last week. Well, only 106,000 CEO shares to go!
Earnings out January 31, before the market opens.
DWCH is now trading at 61% of our valuation.
Now up 101%. HOLD

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $10.80 (Was $9.20, $8.63, $13.77)
PARL closed at $3.94, up $.63.
Lets see, sales up 38%, made $.10 a share fully taxed and paid down $8 million of debt over the past 6 months.
ECOM Ventures announced that it will merge with Model Reorg. Inc. ECOM will pay for it with shares, so that Nussdorf and family will end up owning 70% of ECOM. So maybe this was why he has been selling some PARL shares–lots of expenses and maybe some taxes to pay?
If they can get this deal done, can one with PARL be far behind?
Now trading at 36% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 18%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $20.51 (was $23.22, $20.99, $20.52)
Closed at $9.99 up $.04.
No one cares about this stock right now.
It is a quality company–just French.
For FY2008 (this year) they are STILL projecting another 20% increase in sales and a tripling of operating income. They still have $3.35 a share in cash.
A buy-out is a decent possibility here.
Down 17%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Down $.26 to $6.09.
BDAY announced earnings in early January. We thought they were pretty good. Apparently the market did not agree. Sales were up 10%, gross margin was up to 53%, but operating income was down from $568,000 to $430,000. So we have lost $20 million of market cap for a $138,000 decline in operating income. Cash was $18.7 million or $2.34 per share.
From their conference call, it sounds like 2008 will be a year of continued investment in systems and the business. So maybe no great earnings to propel the stock for a while.
The “turnaround” is not yet done.
We like the recent insider buying again and are content to wait for this one.
Down 27%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) NEW Valuation $13.32 (was $12.89, $13.40)
Up $.16 to $6.86.
UP 6%. BUY

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $11.51
Down $.16 to $4.29.
Earnings out Tuesday February 6th after the close.
Down 41%. HOLD

Angeion Corp. (ANGN-Recommended 10/14/2007)
Buy Price $7.55, Valuation $13.67
UP $.41 to $9.51.
13D filed in January. Don’t know the investor (Pessin) but they have accumulated 206,600 shares or just over 5%.
In this crazy market we are taking our profit in ANGN–just not enough visability on what is going on here. At 70% of our valuation, we will cash out now.
UP 26%. SELL.

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Up $.38 to $1.78.
Settled some litigation last week–good news. Take-over rumours around too.
Down 25%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $20.04, Valuation $24.00 to $30.00
Down $1.41 to $14.07.
Time to double-up here. This is stupid in our opinion. New average buy price will be $16.53.
PDLI announced the sale of a $30 million a year in sales drug–for $200 million.
Looks like our 3X product revenue valuation may be a tad low (below). The stock sank on this news. Makes no sense to us–other than tax loss selling.
At 7X the royalty revenue and 3X the product sales, you get $2.1 billion in value comapared to the current market cap of $2.1 billion. Their pipeline, and know-how has to be worth something.
No matter, they are still trying to sell the company.
So we are just waiting for them to announce the sale of the company and for how much.
Down 30%. BUY

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $9.39
Up $.21 to $3.93.
There is value here.
Trading at only 42% of our valuation.
Earnings out Wednesday, February 6th after the close.
Down 8%. BUY

OB-abies (Bulletin Board Listed Stocks)

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.62, down $.03.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 1%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.15, down $.07.
OPTIO has cash of $.41 per share–34% of the market cap.
In late June, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division. In other words, a “for sale” sign has gone up. Having been through their SEC filings, there appears to be no disclosure on the sales or operating results for this “division”, so there is no way for us to determine what this could mean from a valuation standpoint.
It has been over 6 months now since their announcement–We would expect to hear an update SOON. They said in their latest earnings release that their healthcare business exceeded their goals. They better get a good price for this.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers, or they get a good deal on the Healthcare “division”.
Down 8%. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.05 (was $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.90, up $.06.
Nice presentation filed in their 8K in December. Couple of nice mentions–including in Smart Money of the CEO interview with the Wall Street Reporter. Sigma Opportunity Fund has been buying more shares.
We are guessing $55 million of revenue this year and being profitable–which should yield a valuation of over $3.50 a share, and hopefully a share price of at least $2.00–up 100% from here.
No news.
Now down 3%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.28.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.08 Valuation $2.08
Closed at $.90, down $.06.
LTUS announced the hiring of a PR firm last week. They need to get to work!
LTUS, filed an impressive investor presentation on Form 8K in early December.
As noted, China stocks are risky, but based on their published information we just cannot figure out why this stock is trading so low.
LTUS is on track to make $.18 a share this year. Even if these earnings were taxed at U.S. tax rates, that would be about $.12 a share. That is a PE of less than 10, for a company growing revenues at 50% year-over-year. We may continue to buy more if the price stays in this range.
Down 17%. BUY

Seems like things are only getting worse in the market! Everything got hammered again last week. We were at least down less than the averages for the first time this year. DWCH was our star last week–up 22%. PARL was our biggest dog last week, down 18%.

All of the major averages have lost all their 2007 gains and then some. While our year has stunk up the place–we are still holding onto about 3% of our 2007 gain. Really doesn’t make us feel too much better.

We were down another 3.0% last week, bringing our 2008 loss to 17.2%. NASDAQ was down 4.1%, the DOW was down 4.0% and the S+P 500 was down 5.4%.

Last week we went 3 stocks up, 10 down and 2 even.

For last week, 2008 year-to-date, and since we started this Blog in January 2006, our model portfolio is -3.0%,-17.2% and +18.7% respectively. Since inception we are now 20 stocks up and 12 down( 2 of which are down less than 10%).

So far in 2008 the DOW is down 8.8%, NASDAQ is down 11.8% and the S+P 500 is down 9.8%.

The Russell 3000 and the Wilshire 5000 are both down about 10% this year.

Since inception we have closed out the following positions:

2006-NTCT +44%
2006-ONXS +11% (Buyout offer)
2006-DTLK +41%
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-RITT +62%
2007-MIVA +55%
2007-DTLK +25% (2 weeks)
2007-PDLI + 3% (Waited too long to sell)
2007-QADI +25%
2007-CIMT +50%
2007-BDR +19%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.

The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).

For the 16 stocks that we closed out in 2006 and 2007 the average gain was 22%.

Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $10.65, Valuation $20-$22
Down $1.02 to $13.30.
The market just stinks, hackers are at work (even though short interest dropped a bit)
Things continue to look just fine here.
Now up 25%. HOLD.

DataWatch Corp. (DWCH-Recommended 2/12/2006)
Buy price $3.21 (averaged down from $3.66), Valuation $10.30 (was $9.28, $9.20, $8.32, $7.50, $7.63, $9.31)
Closed at $6.57, up $1.17.
The ex-CEO keeps cashing in options and selling–another 20,000 shares sold last week. Well only 126,000 CEO shares to go!
Earnings out January 31, before the market opens.
DWCH is now trading at 64% of our valuation.
Now up 109%. HOLD

Parlux Fragrances (PARL-Recommended 11/30/2006)
Buy price $4.78 (was $6.12 before another $10,000 added, $6.65 before double up), Valuation $10.80 (Was $9.20, $8.63, $13.77)
PARL closed at $3.31, down $.71.
Lets see, sales up 38%, made $.10 a share fully taxed and paid down $8 million of debt over the past 6 months.
ECOM Ventures announced that it will merge with Model Reorg. Inc. ECOM will pay for it with shares, so that Nussdorf and family will end up owning 70% of ECOM. So maybe this was why he has been selling some PARL shares–lots of expenses and maybe some taxes to pay?
If they can get this deal done, can one with PARL be far behind?
Now trading at 31% of our valuation.
The new management has 2.0 million reasons to make this stock go up. Glenn Nussdorf paid $6 for his shares.
Down 31%. BUY.

ILOG SA (ILOG-recommended 3/26/2007)
Buy price $12.08 (was $12.92 before another $10,000 added, $13.60 before double-up), Valuation $20.51 (was $23.22, $20.99, $20.52)
Closed at $9.95 down $.55.
No one cares about this stock right now.
It is a quality company–just French.
For FY2008 (this year) they are STILL projecting another 20% increase in sales and a tripling of operating income. They still have $3.35 a share in cash.
A buy-out is a decent possibility here.
Down 18%. HOLD

Celebrate Express (BDAY-recommended 4/17/2007)
Buy Price $8.38 (was $8.82 before double-up), Valuation $15.51 (Was $17.85 $18.18)
Up $.35 to $6.35.
BDAY announced earnings in early January. We thought they were pretty good. Apparently the market did not agree. Sales were up 10%, gross margin was up to 53%, but operating income was down from $568,000 to $430,000. So we have lost $20 million of market cap for a $138,000 decline in operating income. Cash was $18.7 million or $2.34 per share.
From their conference call, it sounds like 2008 will be a year of continued investment in systems and the business. So maybe no great earnings to propel the stock for a while.
The “turnaround” is not yet done.
We like the recent insider buying again and are content to wait for this one.
Down 24%. BUY.

Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.52, (was $6.67 ($10,000 added), $6.98 after double up) NEW Valuation $13.32 (was $12.89, $13.40)
Down $.35 to $6.70.
Penninsula Capital owns 1.67 million shares or over 20% of MEDW. Not sure how they liguidate there stake profitably without a takeover
UP 3%. BUY

Candela Corp. (CLZR-Recommended 8/30/2007)
Buy Price $7.26, Valuation $11.51
Down $.10 to $4.45.
No news.
Down 39%. HOLD

Angeion Corp. (ANGN-Recommended 10/14/2007)
Buy Price $7.55, Valuation $13.67
UP $.05 to $9.10.
13D filed in January. Don’t know the investor (Pessin) but they have accumulated 206,600 shares or just over 5%.
No news.
UP 21%. HOLD

MIVA. (MIVA-Recommended 10/21/2007)
Buy Price $2.38 (Was $2.62 before another $10,000 and was $3.00 before double up), Valuation $7.58 (was $7.59)
Down $.12 to $1.40.
Down 41%. BUY

PDL Biopharma. (PDLI-Recommended 10/21/2007)
Buy Price $20.04, Valuation $24.00 to $30.00
Down $.79 to $15.48.
PDLI announced the sale of a $30 million a year in sales drug–for $200 million.
Looks like our 3X product revenue valuation may be a tad low (below). The stock sank on this news. Makes no sense to us–other than tax loss selling.
At 7X the royalty revenue and 3X the product sales, you get $2.1 billion in value comapared to the current market cap of $2.1 billion. Their pipeline, and know-how has to be worth something.
No matter, they are still trying to sell the company.
So we are just waiting for them to announce the sale of the company and for how much.
Down 23%. BUY

Datalink. (DTLK-Recommended 10/31/2007)
Buy Price $4.28, Valuation $9.39
Down $.14 to $3.72.
There is value here.
Got a nice plug in Barron’s, and they presented at Needham recently.
Not enough to keep the price from falling in this bad market.
Trading at only 40% of our valuation.
Earnings out Wednesday, February 6th after the close.
Down 13%. BUY

OB-abies (Bulletin Board Listed Stocks)

ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up), Valuation $5.71 (was $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.65, upchanged.
Earnings announced last month were great. Sales up 21% and they made money. This market just stinks for mini/micro caps, and ARI does little to get any investor attention. Wake up management–you have a great little company here worth 3X what it is selling for.
Now up 2%. BUY. Still a Huge valuation gap here.

OPTIO Software Inc. (OPTO.ob-Recommended 3/22/2006)
Buy price $1.25, Valuation $2.74 (was $2.34, $2.28, $2.89, $2.89, $2.54 and 2.88)
Closed at $1.22, up $.01.
OPTIO has cash of $.41 per share–34% of the market cap.
In late June, OPTIO announced they had hired an investment banker to help them review the “Strategic Alternatives” related to their Healthcare software division. In other words, a “for sale” sign has gone up. Having been through their SEC filings, there appears to be no disclosure on the sales or operating results for this “division”, so there is no way for us to determine what this could mean from a valuation standpoint.
It has been over 6 months now since their announcement–We would expect to hear an update SOON. They said in their latest earnings release that their healthcare business exceeded their goals. They better get a good price for this.
Still hoping we will see north of $2.00–but may not happen now unless next quarter rebounds with some decent profit numbers, or they get a good deal on the Healthcare “division”.
Down 2%. HOLD.

Avatech Solutions Inc. (AVSO.ob-Bought November 28, 2005)
Buy price $.93 (Was $.99 and $1.19 before adding $10,000-twice), Valuation $3.05 (was $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.84, down $.05.
Nice presentation filed in their 8K in December. Couple of nice mentions–including in Smart Money of the CEO interview with the Wall Street Reporter. Sigma Opportunity Fund has been buying more shares.
We are guessing $55 million of revenue this year and being profitable–which should yield a valuation of over $3.50 a share, and hopefully a share price of at least $2.00–up 100% from here.
No news.
Now down 10%. BUY.

CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask, Valuation $1.17 (Was $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price unchanged at $.34. Closed at $.28.
Maybe these guys will wake up and create some shareholder value in 2008.
This is still trading at only 30% of our latest valuation.
Up 26% based on the ASK price. BUY

Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.08 Valuation $2.08
Closed at $.96, down $.03.
LTUS announced the hiring of a PR firm last week. They need to get to work!
LTUS, filed an impressive investor presentation on Form 8K in early December.
As noted, China stocks are risky, but based on their published information we just cannot figure out why this stock is trading so low.
LTUS is on track to make $.18 a share this year. Even if these earnings were taxed at U.S. tax rates, that would be about $.12 a share. That is a PE of less than 10, for a company growing revenues at 50% year-over-year. We may continue to buy more if the price stays in this range.
Down 11%. BUY